Peptide LibraryAmycretin dosage in published studies and labels
These are the doses used for Amycretin in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Amycretin (now named zenagamtide) has no approved dosage. Human dosing comes from Novo Nordisk's phase 1 and phase 2 trials of two forms: once-weekly injections under the skin, escalated from 0.2–0.3 mg to maintenance doses of 0.4–60 mg, and once-daily tablets of 6–50 mg. In type 2 diabetes, weekly injections of 0.4–40 mg lowered HbA1c by 0.9 to 1.7 points over 36 weeks, and phase 3 trials are under way.
| Human dosing established | Yes |
|---|---|
| Route | Subcutaneous · Oral |
| Frequency | Once weekly (injection) or once daily (tablet) |
| Duration studied | 12–36 weeks in the published trials |
| Titration | Dose escalation every 4 weeks from a 0.2 mg starting dose to the maintenance dose in the subcutaneous phase 2 trial; escalation every 4 weeks in the oral phase 2 trial. |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Phase 2 dose-finding, weekly injection, type 2 diabetes (NCT06542874)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 trial | Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor (n=262) | Maintenance doses of 0.4, 1.5, 5, 10, 20 or 40 mg, escalated from 0.2 mg | Subcutaneous | Once weekly | 36 weeks | HbA1c change from -0.9% (0.4 mg) to -1.7% (40 mg); mostly mild to moderate gastrointestinal events | Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: phase 2 trial. Lancet. 2026. |
| Phase 2 dose-finding, daily tablet, type 2 diabetes (NCT06542874)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 trial | Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor (n=186) | 6, 25 or 50 mg | Oral | Once daily | 36 weeks | HbA1c change -0.9% (6 mg), -1.3% (25 mg) and -1.4% (50 mg); all three doses beat placebo | Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: phase 2 trial. Lancet. 2026. |
| Phase 1b/2a, weekly injection, overweight or obesity (NCT06064006)Clinical trial · Randomized, placebo-controlled phase 1b/2a study | Adults aged 18–55 with overweight or obesity (n=125) | Escalated from 0.3 mg to maintenance doses of 1.25, 5, 20 or 60 mg | Subcutaneous | Once weekly | 20–36 weeks | Mean weight change -9.7% (1.25 mg, week 20), -16.2% (5 mg, week 28), -22.0% (20 mg, week 36) and -24.3% (60 mg, week 36); many participants withdrew | Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025. |
| Phase 1 first-in-human, oral (NCT05369390)Clinical trial · Randomized, double-blind, placebo-controlled phase 1 trial | Adults aged 18–55 with overweight or obesity (n=144) | Single doses of 1–25 mg; daily doses of 3–12 mg for 10 days; escalation up to 50 mg or 2 × 50 mg daily for 12 weeks | Oral | Single dose or once daily | 1 day to 12 weeks | Mild or moderate adverse events, mostly gastrointestinal, more frequent at higher doses; exposure was dose-proportional | Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1 trial. Lancet. 2025. |
Where sources disagree
- Injected and oral amycretin use very different amounts: weekly injections of 0.4–60 mg against daily tablets of 6–50 mg. A dose of one form is not a dose of the other, so no single range describes both.
- The largest weight losses come from small early-phase cohorts with many withdrawals. Phase 3 trials have not reported, and amycretin is not FDA-approved.
- Amycretin is one molecule acting on GLP-1 and amylin receptors. It is not the same as CagriSema, which combines two separate molecules, cagrilintide and semaglutide.